Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANNXNASDAQ:OCSNASDAQ:XERSNYSE:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$1.31-7.5%$2.56$1.29▼$7.85$143.17M1.241.79 million shs754,683 shsOCSOculis$15.50-4.5%$19.47$10.79▼$23.08$676.94M0.1947,042 shs17,453 shsXERSXeris Biopharma$3.90-10.0%$4.37$1.69▼$6.07$598.06M1.371.84 million shs2.20 million shsZYMEZymeworks$9.14-8.6%$12.86$7.97▼$17.70$634.54M1.18615,083 shs639,555 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon-7.79%-27.55%-45.59%-70.66%-77.21%OCSOculis+9.73%-11.26%-11.26%-13.16%+46.31%XERSXeris Biopharma+4.84%-15.92%-5.66%+28.87%+114.36%ZYMEZymeworks+0.91%-16.11%-9.91%-29.23%+6.84%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANNXAnnexon2.466 of 5 stars3.53.00.00.02.71.70.6OCSOculis1.9848 of 5 stars3.53.00.00.02.60.00.6XERSXeris Biopharma4.2354 of 5 stars4.41.00.04.23.61.70.6ZYMEZymeworks2.4601 of 5 stars3.40.00.00.03.63.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon 3.00Buy$18.671,320.60% UpsideOCSOculis 3.00Buy$29.5090.27% UpsideXERSXeris Biopharma 2.80Moderate Buy$6.1056.61% UpsideZYMEZymeworks 2.88Moderate Buy$21.00129.76% UpsideCurrent Analyst Ratings BreakdownLatest ANNX, XERS, OCS, and ZYME Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/13/2025OCSOculisRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$37.00 ➝ $41.003/13/2025OCSOculisChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.003/13/2025OCSOculisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $29.003/11/2025ZYMEZymeworksLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$30.003/10/2025ZYMEZymeworksHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$12.00 ➝ $13.003/7/2025XERSXeris BiopharmaLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$5.00 ➝ $6.003/7/2025XERSXeris BiopharmaCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $6.503/7/2025XERSXeris BiopharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.00 ➝ $4.003/7/2025XERSXeris BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.60 ➝ $8.003/7/2025ZYMEZymeworksCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $19.003/4/2025ANNXAnnexonNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00(Data available from 4/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$3.20 per shareN/AOCSOculis$980K690.75N/AN/A$2.87 per share5.40XERSXeris Biopharma$203.07M2.95N/AN/A($0.05) per share-77.90ZYMEZymeworks$76.30M8.33N/AN/A$6.63 per share1.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$134.24M-$1.02N/AN/AN/AN/A-38.99%-33.90%5/12/2025 (Estimated)OCSOculis-$98.92M-$2.31N/AN/AN/A-8,043.28%-71.31%-56.85%5/14/2025 (Estimated)XERSXeris Biopharma-$62.26M-$0.38N/AN/AN/A-33.69%N/A-17.38%5/8/2025 (Estimated)ZYMEZymeworks-$118.67M-$1.61N/AN/AN/A-182.75%-23.00%-18.04%5/1/2025 (Estimated)Latest ANNX, XERS, OCS, and ZYME EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025XERSXeris Biopharma-$0.07N/AN/AN/A$57.61 millionN/A5/1/2025N/AZYMEZymeworks-$0.45N/AN/AN/A$20.65 millionN/A3/11/2025Q4 2024OCSOculis-$0.48-$0.76-$0.28-$0.76$0.21 millionN/A3/3/2025Q4 2024ANNXAnnexon-$0.28-$0.33-$0.05-$0.33N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/AOCSOculisN/AN/AN/AN/AN/AXERSXeris BiopharmaN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A17.1717.18OCSOculis0.014.024.02XERSXeris BiopharmaN/A1.791.29ZYMEZymeworksN/A4.104.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/AOCSOculis22.30%XERSXeris Biopharma42.75%ZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipANNXAnnexon12.67%OCSOculisN/AXERSXeris Biopharma4.56%ZYMEZymeworks1.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon60109.71 million93.09 millionOptionableOCSOculis243.66 millionN/ANot OptionableXERSXeris Biopharma290153.94 million142.28 millionOptionableZYMEZymeworks46069.58 million67.56 millionOptionableANNX, XERS, OCS, and ZYME HeadlinesRecent News About These CompaniesZymeworks Inc. (NYSE:ZYME) Director Acquires $2,194,212.46 in StockApril 10 at 5:20 AM | americanbankingnews.comZymeworks Inc. (NYSE:ZYME) Receives $21.00 Consensus Price Target from AnalystsApril 10 at 2:07 AM | americanbankingnews.comZymeworks (NYSE:ZYME) Stock Price Down 7.6% - What's Next?April 9 at 9:29 PM | marketbeat.comInsider Buying: Zymeworks Inc. (NYSE:ZYME) Director Acquires 196,438 Shares of StockApril 9 at 7:25 PM | marketbeat.comZymeworks Inc. (ZYME): Among Stocks Insiders Bought in April After Trump’s Tariff RolloutApril 9 at 11:26 AM | insidermonkey.comEcor1 Capital, Llc Buys 196,438 Shares of Zymeworks Inc. (NYSE:ZYME) StockApril 8 at 4:32 AM | insidertrades.comZymeworks Inc. (NYSE:ZYME) Receives Average Recommendation of "Moderate Buy" from AnalystsApril 8 at 2:06 AM | marketbeat.comSchroder Investment Management Group Makes New $4.89 Million Investment in Zymeworks Inc. (NYSE:ZYME)April 7 at 3:52 AM | marketbeat.comRaymond James Financial Inc. Purchases Shares of 60,642 Zymeworks Inc. (NYSE:ZYME)April 6, 2025 | marketbeat.comInsider Buying: Zymeworks Inc. (NYSE:ZYME) Director Acquires 4,397 Shares of StockApril 4, 2025 | marketbeat.comInsider Buying: Zymeworks Inc. (NYSE:ZYME) Director Purchases 74,360 Shares of StockApril 4, 2025 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Director Purchases $51,664.75 in StockApril 3, 2025 | insidertrades.comZymeworks Inc. sees insider purchases totaling $1.5 millionApril 2, 2025 | investing.comEcor1 Capital, Llc Buys 43,848 Shares of Zymeworks Inc. (NYSE:ZYME) StockMarch 28, 2025 | marketbeat.comInsider Buying: Zymeworks Inc. (NYSE:ZYME) Director Purchases 43,848 Shares of StockMarch 28, 2025 | insidertrades.comZymeworks Inc.: Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual MeetingMarch 26, 2025 | finanznachrichten.deInsiders Make Huge Purchases of These 4 Biotech StocksMarch 26, 2025 | 247wallst.comZymeworks to Engage Investors at Upcoming ConferencesMarch 26, 2025 | tipranks.comZymeworks Announces Participation in Upcoming Investor ConferencesMarch 26, 2025 | globenewswire.comZymeworks Inc. (NYSE:ZYME) Director Acquires $296,772.12 in StockMarch 25, 2025 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Director Purchases $396,601.74 in StockMarch 25, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANNX, XERS, OCS, and ZYME Company DescriptionsAnnexon NASDAQ:ANNX$1.31 -0.11 (-7.46%) As of 01:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Oculis NASDAQ:OCS$15.57 -0.67 (-4.10%) As of 01:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.Xeris Biopharma NASDAQ:XERS$3.90 -0.44 (-10.05%) As of 01:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.Zymeworks NYSE:ZYME$9.14 -0.86 (-8.60%) As of 01:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom's Big Outperformance Shows Strength Amid Tariff Decline Delta, Walmart Cut Profit Targets: Could Start Domino Effect Joby Aviation: Operational Momentum vs. Market Sentiment Carvana: Can Turnaround Strength Outdrive Market Headwinds? Is Alphabet a Generational Buying Opportunity at These Levels? Meta Seeks Trump's Help in FTC Trial: The Implications Are Huge Is Microsoft Stock Too Cheap to Ignore After Its Latest Drop? Harley-Davidson Tops Watchlists: Value Trap or Turnaround Play? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
